<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01964365</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWJ1330001</org_study_id>
    <nct_id>NCT01964365</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Drug Interaction Study Between Rosuvastatin and Fenofibric Acid in Healthy Male Volunteers</brief_title>
  <official_title>An Open-label, Randomized, 6-Sequence, 3-Period Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between Rosuvastatin and Fenofibric Acid in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics profile and drug-drug
      interaction between rosuvastatin and fenofibric acid in healthy adult subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Multiple blood sample will be collected for 24 hours after last dosing in each of the periods</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau</measure>
    <time_frame>Multiple blood sample will be collected for 24 hours after last dosing in each of the periods</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmin</measure>
    <time_frame>Multiple blood sample will be collected for 24 hours after last dosing in each of the periods</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Multiple blood sample will be collected for 24 hours after last dosing in each of the periods</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>Multiple blood sample will be collected for 24 hours after last dosing in each of the periods</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>Multiple blood sample will be collected for 24 hours after last dosing in each of the periods</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic Ratio</measure>
    <time_frame>Multiple blood sample will be collected for 24 hours after last dosing in each of the periods</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple dose of Rosuvastatin 20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fenofibric acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple dose of Fenofibric acid 135mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin + Fenofibric acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple dose of the combination of Rosuvastatin 20mg and Fenofibric acid 135mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cresto 20mg</intervention_name>
    <description>tablet, rosuvastatin 20mg</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibric acid 135mg</intervention_name>
    <description>capsule, fenofibric acid 135mg</description>
    <arm_group_label>Fenofibric acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cresto 20mg, Fenofibric acid 135mg</intervention_name>
    <description>rosuvastatin 20mg, Fenofibric acid 135mg</description>
    <arm_group_label>Rosuvastatin + Fenofibric acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult male volunteers aged 19 to 45 years

          2. A sybject who has judged to be healthy by the investigator to participate in this
             study based on screening result

          3. A subject who provided written informed consent to participate in this study and
             cooperative with regared to compliance with study related constraints

        Exclusion Criteria:

          1. A subject with sign or symptoms or previously diagnosed disease of liver, digestive
             system, cardiovascular, kidney, respiratory, endocrinology, neurology, immune system,
             hematology, and psychology function or other significant disease and history.

          2. A subject who shows the following result in clinical laboratory test

               -  AST, ALT &gt; 1.25 times of the upper limit of normal range

               -  PR ≥ 210 msec

               -  QRS ≥ 120 msec

               -  QT ≥ 500 msec

               -  QTcF ≥ 500 msec

          3. Subject who has taken other clinical medication from another clinical trial within
             60-day period prior to the first administration of the study medication
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Gook Shin, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>BUSAN PAIK HOSPITAL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inje University College of Medicine Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2013</study_first_submitted>
  <study_first_submitted_qc>October 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2013</study_first_posted>
  <last_update_submitted>February 12, 2014</last_update_submitted>
  <last_update_submitted_qc>February 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Fenofibric acid</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

